Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | HTR7 | P34969 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12629144 | 0.87 | KMT2A (0.47) | DRD2HTR1AHTR2AHTR2CSLC6A4 | |
| SCHEMBL21427218 | 0.81 | KMT2A (0.41) | DRD2HTR2AHTR2CSLC6A4KMT2A | |
| SCHEMBL12629018 | 0.79 | KMT2A (0.44) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL9269191 | 0.76 | KMT2A (0.39) | DRD2KMT2AALDH1A1 | |
| SCHEMBL24922917 | 0.75 | POLB (0.44) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL21211613 | 0.74 | HTR7 (0.36) | DRD2HTR1AHTR7DRD4HTR2A | |
| SCHEMBL16656258 | 0.74 | PAOX (0.47) | DRD2HTR1AHTR7DRD4SIGMAR1 | |
| SCHEMBL12629021 | 0.74 | ALDH1A1 (0.39) | KMT2AALDH1A1 | |
| SCHEMBL21211641 | 0.74 | CXCR4 (0.51) | DRD2HTR1AHTR7DRD4KMT2A | |
| SCHEMBL10033374 | 0.73 | KMT2A (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730897-B2 | Manganese chelate compounds | GE HEALTHCARE AS (NO) | 2020-08-04 | — | — | US | disclosed |
| EP-3558394-B1 | TETRAAZABICYCLO-MACROCYCLE BASED MANGANESE CHELATE COMPOUNDS SUITABLE AS MRI IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2020-06-03 | — | — | EP | disclosed |
| US-20200062791-A1 | MANGANESE CHELATE COMPOUNDS | GE HEALTHCARE AS (NO) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062791-A1 | MANGANESE CHELATE COMPOUNDS | MPI, SLC39A3, SLC39A14 | DRD2 2259/4885HTR1A 4761/4885HTR7 4480/4885 |
| US-10730897-B2 | Manganese chelate compounds | MPI, SLC39A3, SLC39A14 | DRD2 2259/4885HTR1A 4761/4885HTR7 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.